Clinical features and long-term outcomes of patients with systemic polyarteritis nodosa diagnosed since 2005: Data from 196 patients.


Journal

Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164

Informations de publication

Date de publication:
09 2023
Historique:
received: 04 03 2023
revised: 19 06 2023
accepted: 11 07 2023
medline: 22 8 2023
pubmed: 4 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

The landscape of polyarteritis nodosa (PAN) has substantially changed during the last decades. Recent data regarding causes, characteristics, and prognosis of systemic PAN in the modern era are lacking. This retrospective study included patients with systemic PAN referred to the French Vasculitis Study Group between 2005 and 2019. Characteristics, associated conditions and outcomes were collected, and predictors of relapse and death were analyzed. 196 patients were included. Main clinical symptoms were constitutional (84%), neurological (59%), skin (58%) and musculoskeletal (58%) manifestations. Secondary PAN accounted for 55 (28%) patients, including myelodysplastic syndrome (9%), solid cancer (7%), lymphoma (4%) and autoinflammatory diseases (4%). No patient had active HBV infection. All treated patients (98.5%) received glucocorticoids (GCs), alone (41%) or in combination with immunosuppressants (59%), with remission achieved in 90%. Relapses were independently associated with age >65 years (HR 1.85; 95% CI1.12-3.08), gastrointestinal involvement (1.95; 95% CI1.09-3.52) and skin necrotic lesions (HR 1.95; 95%CI 1.24-3.05). One-, 5- and 10-year overall survival rates were 93%, 87% and 81%, respectively. In multivariate analyses, age >65 years (HR 2.80; 95%CI 1.23-6.37), necrotic purpura (HR 4.16; 95%CI 1.62-10.70), acute kidney injury (HR 4.89; 95% 1.71-13.99) and secondary PAN (HR 2.98; 95%CI 1.29-6.85) were independently associated with mortality. Landscape of PAN has changed during the last decades, with the disappearance of HBV-PAN and the emergence of secondary PAN. Relapse rate remains high, especially in aged patients with gastrointestinal and cutaneous necrosis, as well as mortality.

Sections du résumé

BACKGROUND
The landscape of polyarteritis nodosa (PAN) has substantially changed during the last decades. Recent data regarding causes, characteristics, and prognosis of systemic PAN in the modern era are lacking.
METHODS
This retrospective study included patients with systemic PAN referred to the French Vasculitis Study Group between 2005 and 2019. Characteristics, associated conditions and outcomes were collected, and predictors of relapse and death were analyzed.
RESULTS
196 patients were included. Main clinical symptoms were constitutional (84%), neurological (59%), skin (58%) and musculoskeletal (58%) manifestations. Secondary PAN accounted for 55 (28%) patients, including myelodysplastic syndrome (9%), solid cancer (7%), lymphoma (4%) and autoinflammatory diseases (4%). No patient had active HBV infection. All treated patients (98.5%) received glucocorticoids (GCs), alone (41%) or in combination with immunosuppressants (59%), with remission achieved in 90%. Relapses were independently associated with age >65 years (HR 1.85; 95% CI1.12-3.08), gastrointestinal involvement (1.95; 95% CI1.09-3.52) and skin necrotic lesions (HR 1.95; 95%CI 1.24-3.05). One-, 5- and 10-year overall survival rates were 93%, 87% and 81%, respectively. In multivariate analyses, age >65 years (HR 2.80; 95%CI 1.23-6.37), necrotic purpura (HR 4.16; 95%CI 1.62-10.70), acute kidney injury (HR 4.89; 95% 1.71-13.99) and secondary PAN (HR 2.98; 95%CI 1.29-6.85) were independently associated with mortality.
CONCLUSION
Landscape of PAN has changed during the last decades, with the disappearance of HBV-PAN and the emergence of secondary PAN. Relapse rate remains high, especially in aged patients with gastrointestinal and cutaneous necrosis, as well as mortality.

Identifiants

pubmed: 37536165
pii: S0896-8411(23)00102-6
doi: 10.1016/j.jaut.2023.103093
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103093

Investigateurs

Felix Ackermann (F)
Olivier Aumaitre (O)
Guillaume Bussone (G)
Pilartxo Catalan (P)
François Chasset (F)
Yoann Crabol (Y)
Claire de Moreuil (C)
Arnaud Hot (A)
Marc Humbert (M)
Noémie Jourde Chiche (NJ)
Thomas Le Gallou (T)
Dominique Leroux (D)
Rafik Mesbah (R)
Luc Mouthon (L)
Christian Pagnoux (C)
Sabine Revuz (S)
Laurent Rieu (L)
Jean Schmidt (J)
Frederic Vandergheynst (F)

Informations de copyright

Copyright © 2023. Published by Elsevier Ltd.

Auteurs

Julien Rohmer (J)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.

Yann Nguyen (Y)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France; Autoimmunity Team, Immunology of Viral Infections and Autoimmune Diseases, INSERM U1184, Université Paris Saclay, Le Kremlin-Bicêtre, France.

Ludovic Trefond (L)

Department of Internal Medicine, CHU, Clermont Ferrand, France.

Christian Agard (C)

Nantes Université, CHU Nantes, Service de médecine interne, F-44000, Nantes, France.

Jean Sebastien Allain (JS)

Department of Internal Medicine, CHRU, Rennes, France.

Alice Berezne (A)

Department of Internal Medicine, CH, Annecy, Genevois, France.

Pierre Charles (P)

Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France.

Pascal Cohen (P)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.

Guillaume Gondran (G)

Department of Internal Medicine and dermatology, CHU, Limoges, France.

Matthieu Groh (M)

Department of Internal Medicine, National Reference Center for Hypereosinophilic Syndromes, Foch Hospital, Suresnes, France; University of Lille, INSERM U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.

Tessa Huscenot (T)

Department of Internal Medicine, Hôpital Ambroise Parée, Paris, France.

Carole Lacout (C)

Department of Internal Medicine and Clinical Immunology, CHU, Angers, France.

Estibaliz Lazaro (E)

Department of Internal Medicine, Hôpital Haut Leveque, CHU, Bordeaux, France.

Jonathan London (J)

Department of Internal Medicine, Hôpital de la Croix Saint Simon, Paris, France.

François Maurier (F)

Department of Internal Medicine, CHU, Metz, France.

Arsène Mekinian (A)

Department of Internal Medicine, Hôpital Saint Antoine, AP-HP, Sorbonne Université, Paris, France.

Rafik Mesbah (R)

Department of Internal Medicine, CH, de Boulogne sur Mer, France.

Isabelle Nubourgh (I)

Department of Internal Medicine, Université libre de Bruxelles, Belgique.

Laurent Perard (L)

Department of Internal Medicine, Hôpital Saint Joseph Saint Luc, Lyon, France.

Xavier Puéchal (X)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.

Gregory Pugnet (G)

Department of Internal Medicine and clinical immunology, CHU, Toulouse, France.

Mathieu Puyade (M)

Department of Internal Medicine, CHU, Poitier, France.

Viviane Queyrel (V)

Rheumatologie, Hôpital Pasteur, CHU, Nice, France.

Arthur Roux (A)

Department of Nephrology, HEGP, Paris, France.

Diane Rouzaud (D)

Department of Internal Medicine, Hôpital Bichat, Paris, France.

Cecile-Audrey Durel (CA)

University Paris-Cité, F-75006, Paris, France.

Loïc Guillevin (L)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France.

Benjamin Terrier (B)

Department of Internal Medicine, Hôpital Cochin, AP-HP.Centre, Université Paris Cité, Paris, France; University Paris-Cité, F-75006, Paris, France. Electronic address: benjamin.terrier@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH